Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome
Lingyu Tian, Jiaqiang Ma, Lijie Ma, et al.
World Journal of Surgical Oncology (2020) Vol. 18, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 90
The role of tumor-infiltrating lymphocytes in cholangiocarcinoma
Dong Liu, Lara R. Heij, Zoltán Czigány, et al.
Journal of Experimental & Clinical Cancer Research (2022) Vol. 41, Iss. 1
Open Access | Times Cited: 89
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study
Guo–Ming Shi, Xiaoyong Huang, Dong Wu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 80
Tumor-infiltrating T lymphocytes: A promising immunotherapeutic target for preventing immune escape in cholangiocarcinoma
Sijia Hua, Xinyi Gu, Hangbin Jin, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 177, pp. 117080-117080
Open Access | Times Cited: 8
IL-21 and IL-33 May Be Effective Biomarkers to Predict the Efficacy of PD-1 Monoclonal Antibody for Advanced Cholangiocarcinoma
Haijiao Yan, Qian Deng, Yu Meng, et al.
Cancer Biotherapy and Radiopharmaceuticals (2025)
Closed Access | Times Cited: 1
Lacking Immunotherapy Biomarkers for Biliary Tract Cancer: A Comprehensive Systematic Literature Review and Meta-Analysis
Giorgio Frega, Fernando P. Cossío, Jesús M. Bañales, et al.
Cells (2023) Vol. 12, Iss. 16, pp. 2098-2098
Open Access | Times Cited: 19
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
Xianzhe Yu, Lingling Zhu, Ting Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 16
Unveiling the promise of PD1/PD-L1: A new dawn in immunotherapy for cholangiocarcinoma
Fei Chen, Jian Sheng, Xiaoping Li, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 175, pp. 116659-116659
Open Access | Times Cited: 5
Case report: Translational treatment of unresectable intrahepatic cholangiocarcinoma: Tislelizumab, Lenvatinib, and GEMOX in one case
Hewei Zhang, Haibo Yu
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 4
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy
Neda Dadgar, Arun Kumar Arunachalam, Hanna Hong, et al.
Cancers (2024) Vol. 16, Iss. 18, pp. 3232-3232
Open Access | Times Cited: 4
Infiltrating T lymphocytes and tumor microenvironment within cholangiocarcinoma: immune heterogeneity, intercellular communication, immune checkpoints
Yunyan Dai, Chenyang Dong, Zhiming Wang, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
The Immune–Genomics of Cholangiocarcinoma: A Biological Footprint to Develop Novel Immunotherapies
Antonella Cammarota, Rita Balsano, Tiziana Pressiani, et al.
Cancers (2025) Vol. 17, Iss. 2, pp. 272-272
Open Access
Management of intrahepatic cholangiocarcinoma: a review for clinicians
Matteo Colangelo, Marcello Di Martino, Michela Anna Polidoro, et al.
Gastroenterology report (2025) Vol. 13
Open Access
Biomarkers for the Evaluation of Immunotherapy in Patients with Cholangiocarcinoma
Thaleia-Eleftheria Bousou, Panagiotis Sarantis, Ioanna A. Anastasiou, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 555-555
Open Access
Research progress of T cells in cholangiocarcinoma
Zhiming Wang, Yunyan Dai, Yunpeng Zhou, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Autoimmune pancreatitis and pancreatic cancer: Epidemiological aspects and immunological considerations
Dimitri Poddighe
World Journal of Gastroenterology (2021) Vol. 27, Iss. 25, pp. 3825-3836
Open Access | Times Cited: 24
Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma
Xing Chen, Jinpeng Du, Jiwei Huang, et al.
Journal of Clinical and Translational Hepatology (2022) Vol. 10, Iss. 3, pp. 553-563
Open Access | Times Cited: 18
Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine
Riccardo Carloni, Alessandro Rizzo, Angela Dalia Ricci, et al.
Translational Oncology (2022) Vol. 25, pp. 101514-101514
Open Access | Times Cited: 17
Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy
Lara R. Heij, Jan Bednarsch, Xiuxiang Tan, et al.
Cells (2023) Vol. 12, Iss. 6, pp. 851-851
Open Access | Times Cited: 10
Tumor immune microenvironment and the current immunotherapy of cholangiocarcinoma (Review)
Siqi Yang, Rui-Qi Zou, Yu-Shi Dai, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 6
Open Access | Times Cited: 7
Fibrinogen/albumin ratio index is an independent predictor of recurrence-free survival in patients with intrahepatic cholangiocarcinoma following surgical resection
Hu Liu, Guoteng Qiu, Fengjuan Hu, et al.
World Journal of Surgical Oncology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 16
PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for patients with intrahepatic cholangiocarcinoma
Lavinia Patricia Mocan, Rareș Crăciun, Cristiana Grapă, et al.
Cancer Immunology Immunotherapy (2022) Vol. 72, Iss. 4, pp. 1003-1014
Open Access | Times Cited: 11
PD-1+ T-Cells Correlate with Nerve Fiber Density as a Prognostic Biomarker in Patients with Resected Perihilar Cholangiocarcinoma
Xiuxiang Tan, Jan Bednarsch, Mika Rosin, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2190-2190
Open Access | Times Cited: 9
Preclinical and clinical studies of immunotherapy for the treatment of cholangiocarcinoma
Xinjun Lu, Benjamin L. Green, Changqing Xie, et al.
JHEP Reports (2023) Vol. 5, Iss. 7, pp. 100723-100723
Open Access | Times Cited: 4
Prognostic value of programmed cell death ligand 1 expression in patients with intrahepatic cholangiocarcinoma: a meta-analysis
Feng Xian, Dacheng Ren, Jun Bie, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top